Director of Clinical Pharmacology, Cambridge, MA

Director Of Clinical Pharmacology, Cambridge, MaIsomorphic Labs is applying frontier AI to help unlock deeper scientific insights, faster breakthroughs, and life-changing medicines with an ambition to solve all disease. Come and be part of an interdisciplinary team driving groundbreaking innovation and play a meaningful role in contributing towards us achieving our ambitious goals, while being a part of an inspiring and collaborative culture. The world we want tomorrow is the one we're building today. It starts with the culture at this company. It starts with you. About IsoIsomorphic Labs (IsoLabs) was launched in 2021 to advance human health by building on and beyond the Nobel-winning AlphaFold system. Since then, our interdisciplinary team of drug discovery experts and machine learning specialists has built powerful new predictive and generative AI models that accelerate scientific discovery at digital speed. Our name comes from the belief that there is an underlying symmetry between biology and information science. By harnessing AI's powerful capabilities, we can use it to model complex biological phenomena to help design novel molecules, anticipate how drugs will perform and develop innovative medicines to treat and cure some of the world's most devastating diseases. We have built a world-leading drug design engine comprising AI models that are capable of working across multiple therapeutic areas and drug modalities. We are continually innovating on model architecture and developing cutting-edge capabilities to advance rational drug design. Every day, and with each new breakthrough, we're getting closer to the promise of digital biology, and achieving our ambitious mission to one day solve all disease with the help of AI.Isomorphic Labs (IsoLabs) is developing and applying frontier AI to help unlock deeper scientific insights, faster breakthroughs, and life-changing medicines. The company's ambitious mission is to one day solve all disease. IsoLabs has built multiple cutting-edge AI models that power our unified drug design engine, which can tackle a broad spectrum of disease areas and modalities. This breakthrough technology will transform how we design new drug candidates and bring new potential medicines to patients. Come and be part of an interdisciplinary team driving groundbreaking innovation. You will play a meaningful role in achieving our ambitious goals, while being a part of an inspiring and collaborative culture. Together, let's build the future of medicine at Isomorphic Labs. Isomorphic Labs was launched in 2021 to advance human health by building on and beyond the Nobel prize-winning AlphaFold system. Since then, our interdisciplinary team of drug discovery experts and machine learning specialists has built powerful new predictive and generative AI models that accelerate scientific discovery at digital speed. Our name comes from the belief that there is an underlying symmetry between biology and information science. By harnessing AI's powerful capabilities, we can use it to model complex biological phenomena to help design novel molecules, anticipate how drug candidates will perform in the clinic and develop medicines to treat and cure some of the world's most devastating diseases. At IsoLabs, we are committed to leveraging state-of-the-art AI to advance precision medicine paradigms and establish new benchmarks for both efficacy and safety by consistently delivering the optimal treatments to the appropriate patients at precisely the right time, which we expect to significantly enhance our overall probability of success. Since our founding, we have grown a world-class interdisciplinary team led by founder and CEO Sir Demis Hassabis and President Max Jaderberg. We have built strategic drug discovery collaborations with partners including Eli Lilly, Novartis and Johnson & Johnson, with the Novartis collaboration expanding in February 2025 to double its original scope. Our internal drug candidate pipeline consists of multiple programs across oncology and immunology. In March 2025, IsoLabs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and Alphabet. In May 2026, IsoLabs raised $2.1 billion in a Series B financing round. This investment will power our world-leading AI drug design engine, scale our business globally and progress our drug candidate pipeline. The round was led by Thrive Capital, and includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, significantly expanding our global capital base. Isomorphic Labs is scaling globally, with headquarters in London and offices in Lausanne, Switzerland and a US base in Cambridge, Massachusetts. We continue to progress our internal candidate programs towards the clinic while advancing across a broad range of modalities including small molecules, molecular glues, peptides, and antibodies.